HOB Biotech Group Corp.,Ltd (SHA:688656)
China
· Delayed Price · Currency is CNY 137.87
-1.23 (-0.88%)
Mar 9, 2026, 3:00 PM CST
SHA:688656 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 398.4 | 391.86 | 382.83 | 311 | 309.16 | Upgrade
|
| Other Revenue | - | 10.48 | 11.57 | 9.39 | 8.55 | Upgrade
|
| Revenue | 398.4 | 402.34 | 394.41 | 320.39 | 317.71 | Upgrade
|
| Revenue Growth (YoY) | -0.98% | 2.01% | 23.10% | 0.84% | 43.20% | Upgrade
|
| Cost of Revenue | - | 145.16 | 149.41 | 118.14 | 98.55 | Upgrade
|
| Gross Profit | 398.4 | 257.18 | 244.99 | 202.26 | 219.16 | Upgrade
|
| Selling, General & Admin | - | 160.69 | 140.05 | 118.76 | 99.87 | Upgrade
|
| Research & Development | - | 45.47 | 46.32 | 38.11 | 31.23 | Upgrade
|
| Other Operating Expenses | 371.74 | 6.47 | 4.83 | 3.64 | 3.32 | Upgrade
|
| Operating Expenses | 371.74 | 213.02 | 191.7 | 160.25 | 134.83 | Upgrade
|
| Operating Income | 26.66 | 44.16 | 53.3 | 42.01 | 84.33 | Upgrade
|
| Interest Expense | - | -2.71 | -2.53 | -1.92 | -1.24 | Upgrade
|
| Interest & Investment Income | - | 0.89 | 3.4 | 6.95 | 13.08 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.53 | -0.01 | -0.15 | -0.46 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.01 | -0.36 | -0.27 | -0.18 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 24.66 | 41.46 | 53.89 | 46.71 | 95.72 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.43 | 0.22 | 0.01 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.75 | 0.03 | -0.47 | -0.08 | Upgrade
|
| Asset Writedown | - | -1.1 | - | - | - | Upgrade
|
| Other Unusual Items | - | 1.43 | 2.28 | 0.02 | 3.48 | Upgrade
|
| Pretax Income | 24.66 | 41.03 | 56.63 | 46.48 | 99.13 | Upgrade
|
| Income Tax Expense | 1.24 | 4.23 | 9.29 | 4.83 | 12.93 | Upgrade
|
| Net Income | 23.42 | 36.8 | 47.33 | 41.65 | 86.19 | Upgrade
|
| Net Income to Common | 23.42 | 36.8 | 47.33 | 41.65 | 86.19 | Upgrade
|
| Net Income Growth | -36.37% | -22.24% | 13.64% | -51.68% | 52.24% | Upgrade
|
| Shares Outstanding (Basic) | 63 | 62 | 63 | 63 | 62 | Upgrade
|
| Shares Outstanding (Diluted) | 63 | 63 | 64 | 63 | 62 | Upgrade
|
| Shares Change (YoY) | -0.26% | -0.79% | 1.35% | 2.50% | 30.49% | Upgrade
|
| EPS (Basic) | 0.37 | 0.59 | 0.75 | 0.66 | 1.40 | Upgrade
|
| EPS (Diluted) | 0.37 | 0.58 | 0.74 | 0.66 | 1.40 | Upgrade
|
| EPS Growth | -36.21% | -21.62% | 12.12% | -52.86% | 16.67% | Upgrade
|
| Free Cash Flow | - | -54.15 | -75.34 | -161.9 | -63.09 | Upgrade
|
| Free Cash Flow Per Share | - | -0.85 | -1.18 | -2.56 | -1.02 | Upgrade
|
| Dividend Per Share | - | 0.300 | 0.400 | 0.300 | 0.530 | Upgrade
|
| Dividend Growth | - | -25.00% | 33.33% | -43.40% | 76.67% | Upgrade
|
| Gross Margin | 100.00% | 63.92% | 62.12% | 63.13% | 68.98% | Upgrade
|
| Operating Margin | 6.69% | 10.98% | 13.51% | 13.11% | 26.54% | Upgrade
|
| Profit Margin | 5.88% | 9.15% | 12.00% | 13.00% | 27.13% | Upgrade
|
| Free Cash Flow Margin | - | -13.46% | -19.10% | -50.53% | -19.86% | Upgrade
|
| EBITDA | 65.81 | 83.31 | 86.41 | 68.95 | 104.06 | Upgrade
|
| EBITDA Margin | 16.52% | 20.71% | 21.91% | 21.52% | 32.76% | Upgrade
|
| D&A For EBITDA | 39.14 | 39.14 | 33.12 | 26.94 | 19.73 | Upgrade
|
| EBIT | 26.66 | 44.16 | 53.3 | 42.01 | 84.33 | Upgrade
|
| EBIT Margin | 6.69% | 10.98% | 13.51% | 13.11% | 26.54% | Upgrade
|
| Effective Tax Rate | 5.02% | 10.31% | 16.41% | 10.39% | 13.05% | Upgrade
|
| Revenue as Reported | - | 402.34 | 394.41 | 320.39 | 317.71 | Upgrade
|
| Advertising Expenses | - | 10.05 | 9.61 | 8.73 | 6.51 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.